Authors: Wilding JPH, Batterham RL, Calanna S, et al.
-14.9% mean reduction in total body weight at week 68
In this double-blind trial, 1,961 adults with a body-mass index of 30 or greater without diabetes were randomly assigned in a 2:1 ratio to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention.
The seminal STEP 1 clinical trial demonstrating average weight reductions of 14.9% in the semaglutide group versus 2.4% with placebo at 68 weeks.
* Educational commentary prepared by Peptide Health Digest editors to provide context on study methodology.
Wilding JPH, Batterham RL, Calanna S, et al.
This study record was compiled from public biomedical repositories for educational and informational reference. Peptide Health Digest does not claim authorship of the original investigation.
